INTRODUCTION
============

Intravascular large B-cell lymphoma (IVLBCL) is a rare form of large B-cell lymphoma with pathological findings of intravascular proliferation and/or sinusoidal involvement of lymphoma cells \[[@b1-kjim-2018-396]\]. IVLBCL is classified as a subtype of extranodal large B-cell lymphoma in the World Health Organization (WHO) classification because of its distinctive clinical features \[[@b2-kjim-2018-396]\]. Although the recently updated WHO classification suggested classic, cutaneous, and hemophagocytic syndrome-associated variants according to clinical and laboratory features, Asian and Western variants according to their geographic distribution were still commonly used \[[@b3-kjim-2018-396],[@b4-kjim-2018-396]\]. Compared with the Western variant, where skin involvement was common, the Asian variant was reported to involve more frequently the liver, spleen, and bone marrow \[[@b5-kjim-2018-396]\]. A hemophagocytic syndrome-associated variant could be referred to as the Asian variant because hemophagocytic lymphohistiocytosis (HLH) was more common in Asian patients with IVLBCL, whereas HLH is a rare event in those with the Western variant \[[@b6-kjim-2018-396]\]. A population-based study of IVLBCL in the United States reported that the incidence of IVLBCL increased significantly from 2000 to 2013 \[[@b7-kjim-2018-396]\]. This might be associated with better understanding of the clinical and laboratory features of this disease entity. Nevertheless, the diagnosis of IVLBL remains problematic, and it is still difficult to diagnose IVLBCL because of the lack of overt lymphadenopathy and peripheral blood involvement. In particular, the Asian variant might be commonly misdiagnosed as other disorders such as infections because of its common association with HLH. Thus, timely diagnosis and immediate treatment remain as a challenge to improve outcomes for patients with the Asian variant.

Given that the Asian variant more frequently presents as stage IV disease involving the liver and bone marrow as well as HLH, the outcome of affected patients might be inferior to that of those with diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS). Furthermore, there are limited data regarding central nervous system (CNS) involvement in the Asian variant because this is relatively more frequent in the Western variant \[[@b5-kjim-2018-396]\]. The negative impact of CNS involvement on the prognosis of DLBCL-NOS was well known even in the era of rituximab \[[@b8-kjim-2018-396]-[@b11-kjim-2018-396]\]. However, there is still no consensus on the treatment approach for CNS involvement in patients with lymphomas including IVLBCL. Therefore, we analyzed the clinical features and treatment outcomes of patients with the Asian variant of IVLBCL and also compared their survival outcomes based on CNS involvement to evaluate its impact on the prognosis.

METHODS
=======

Patients
--------

We reviewed the electronic medical records of patients who were diagnosed with IVLBCL at Samsung Medical Center between 2001 and 2018. The diagnosis was based on histopathological criteria including the presence of CD20-positive neoplastic B cells with large cell morphology and intravascular or sinusoidal proliferation of lymphoma cells. All patients were evaluated for staging work-ups in clinical practice including physical examinations, complete blood cell counts, serum biochemistry, computed tomography scans of chest and abdominal pelvis, bone marrow aspiration and biopsy, and ^18^F-fluorodeoxyglucose positron emission tomography/computed tomography scans. Additional work-up procedures, such as brain or spine magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) analysis, and cytological examination of pleural fluid, were performed if indicated clinically. Stage was determined using the Ann Arbor staging system, and the risk of prognosis was defined by the International Prognostic Index (IPI) consisting of age, Eastern Cooperative Oncology Group performance status, Ann Arbor stage, numbers of extranodal involvements, and serum lactate dehydrogenase (LDH) levels at diagnosis. This study was approved by the Institutional Review Board of Samsung Medical Center, Seoul, Korea, and the requirement for informed consent was waived because of the retrospective nature of the study (IRB File No: 2018-10-065).

Data collection
---------------

After reviewing the medical records, clinical features at the time of diagnosis were collected. CNS involvement was defined as the presence of a lymphoma in the brain parenchyma and/or spinal cord as demonstrated by MRI, or leptomeningeal involvement diagnosed by CSF analysis at the time of diagnosis or during or after treatment. As a predictive model for prognosis as well as CNS involvement, we gathered the data required for CNS-IPI and National Comprehensive Cancer Network (NCCN)-IPI because they showed better prognostic power compared with existing standard IPI \[[@b12-kjim-2018-396],[@b13-kjim-2018-396]\]. As most patients were treated with R-CHOP chemotherapy regimens (rituximab 375 mg/m^2^ on day 1, cyclophosphamide 750 mg/m^2^, doxorubicin 50 mg/m^2^, vincristine 1.4 mg/m^2^ \[maximum 2 mg\] on day 1, and prednisone 100 mg on day 1 to 5), data including the number of cycles and dose intensity (cumulative dose in mg) / (treatment duration in weeks) of R-CHOP were gathered. For patients with CNS involvement, CNS-directed therapy such as intrathecal (IT) or intravenous (IV) methotrexate (MTX) was added to R-CHOP in clinical practice. The IT chemotherapy regimens were MTX-based combination regimens (MTX 15 mg, Ara-C 30 mg/m^2^, hydrocortisone 15 mg/m^2^) or MTX single therapy (MTX 15 mg IT), whereas the IV MTX regimen used 1 to 1.5 g/m^2^ over 6 hours. These data about CNS-directed therapy were also collected. The treatment response to R-CHOP was re-determined by the Revised Response Criteria for Malignant Lymphoma \[[@b14-kjim-2018-396]\]. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) was done in selected patients after the completion of R-CHOP chemotherapy (upfront ASCT) or salvage chemotherapy (salvage ASCT) according to the physicians' discretions. As this was a retrospective study, adverse events and toxicities were based on a review of medical records. According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0, grade 3 or 4 adverse events were recorded.

Statistical analysis
--------------------

Descriptive statistics are reported as proportions and medians. Intergroup comparisons were performed using Fisher's exact test for categorical variables and the Mann-Whitney nonparametric U test for age. Progression-free survival (PFS) was calculated from the date of diagnosis to the first day of disease progression, relapse, death as a result of any cause, or last date of follow-up. Overall survival (OS) was calculated from the date of diagnosis to death or to the last date of follow-up. Survival curves were generated using the Kaplan-Meier method, and survival rates were compared using the log-rank test. Univariate and multivariate analysis was performed using Cox regression analysis. Two-sided *p* values \< 0.05 were considered significant, and statistical analyses were performed using the statistical software package IBM PASW version 18.0 (SPSS Inc., Chicago, IL, USA).

Ethical approval
----------------

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

RESULTS
=======

Characteristics of patients at diagnosis
----------------------------------------

Forty-six patients were diagnosed with IVLBCL, and their median age at diagnosis was 62 years (range, 34 to 82). Male patients predominated (n = 26, 57%), and B symptoms were present in 31 patients (78%) ([Table 1](#t1-kjim-2018-396){ref-type="table"}). Hepatomegaly and/or splenomegaly were observed in 26 patients (57%), whereas lymphadenopathy was less common (n = 22, 48%). Cytopenia affecting the hemoglobin level (\< 11 g/dL) and/or platelet count (\< 100 × 10^9^/L) were also found frequently ([Table 1](#t1-kjim-2018-396){ref-type="table"}). The clinically presenting symptoms were diverse; however, fever was the most common symptom (27/46, 59%) ([Fig. 1A](#f1-kjim-2018-396){ref-type="fig"}). Neurological symptoms, such as diplopia and facial palsy, and altered mental functions were the second most common symptoms (15/46, 33%). Bone marrow and liver were the most commonly involved extranodal organs (54% and 48%, respectively) and were the most common sites of biopsy for diagnosis in this study ([Fig. 1B](#f1-kjim-2018-396){ref-type="fig"}). Accordingly, most patients were at stage IV disease (n = 42, 91%) ([Table 1](#t1-kjim-2018-396){ref-type="table"}). All patients had increased levels of serum LDH, and 30 patients had extremely high levels (more than three times the normal range) ([Table 1](#t1-kjim-2018-396){ref-type="table"} and [Fig. 1C](#f1-kjim-2018-396){ref-type="fig"}). Sixteen patients (35%) had HLH, and four patients showed severe hypercalcemia (up to 1.35 mmol/L). Based on the IPI score, 44 patients (96%) were classed as high-to-intermediate risk or high risk, whereas 44 patients (96%) were classed as having a high-to-intermediate risk or a high risk by NCCN-IPI ([Table 1](#t1-kjim-2018-396){ref-type="table"}). Classification according to the CNS-IPI score showed that 38 patients belonged to the high risk group, while only eight patients were in the low or intermediate risk categories ([Table 1](#t1-kjim-2018-396){ref-type="table"}).

Treatment outcomes
------------------

All patients received R-CHOP as a first-line treatment after diagnosis with a median number of six cycles (range one to eight). At the end of treatment, 31 patients achieved a complete response (CR), whereas eight patients showed disease progression ([Fig. 2](#f2-kjim-2018-396){ref-type="fig"}). Six patients died after the first or second cycle of R-CHOP, and the causes of death were treatment-related adverse events including cytopenia, infectious complications, and pulmonary hemorrhage. One patient was lost to follow-up after the completion of the first cycle. Therefore, the CR rate based on intent to treat was 67% (31/46). According to physicians' decisions, the dosage of R-CHOP was reduced in 13 patients for elderly or frail patients. The administration of rituximab in the first cycle was delayed in 21 patients when considering the risk of infusion-related reaction and rituximab-related severe adverse events. As a result, the median dose-intensity of each drug was as follows: rituximab 200 mg/wk (range, 163 to 240), cyclophosphamide 393 mg/wk (range, 299 to 477), doxorubicin 26 mg/wk (range, 18 to 32), and vincristine 1 mg/wk. The most frequently attenuated drugs were doxorubicin and vincristine, which were reduced by approximately 20% to 25%. However, the overall response rate was not significantly different, regardless of the dose reduction or intensity (data not shown). The most common grade 3 or 4 toxicity seen was neutropenia or febrile neutropenia (n = 26, 57%). Three patients developed pulmonary hemorrhage during the first cycle of R-CHOP, especially immediately after the infusion of rituximab. Two of them recovered; however, one patient died from massive pulmonary hemorrhage and subsequent infectious complications. Infusion-related reactions associated with rituximab such as fever, chills, and dyspnea were also observed in seven patients. Upfront ASCT was done for two patients including one patient with CNS involvement at diagnosis, and these patients were still alive at the time of analysis without evidence of relapse ([Fig. 3](#f3-kjim-2018-396){ref-type="fig"}). On the other hand, the outcome of six patients undergoing salvage ASCT after relapse was poor; thus, only one patient was alive. Likewise, patients with disease progression at the end of treatment with R-CHOP showed dismal prognoses even after salvage chemotherapy except for one ([Fig. 2](#f2-kjim-2018-396){ref-type="fig"}).

CNS involvement and treatment outcomes
--------------------------------------

At diagnosis, 11 patients had CNS involvement (24%) ([Fig. 1B](#f1-kjim-2018-396){ref-type="fig"}), and neurologic signs and symptoms were present in eight of them (8/11; 73%). Neurologic symptoms were heterogeneous, including diplopia, headache, visual defect, hearing difficulty, facial palsy, and mental changes. The diagnosis of CNS involvement was done by CSF analysis via lumbar puncture (n = 6), while the remaining five patients were diagnosed by radiologic imaging such as MRI. Four patients developed CNS involvement during or after treatment with R-CHOP. As a result, 15 of the 46 patients had CNS involvement (33%). A comparison of characteristics at diagnosis between patients with and without CNS involvement did not show significant differences ([Table 2](#t2-kjim-2018-396){ref-type="table"}). However, all patients with CNS involvement belonged to the high-risk group according to CNS-IPI, whereas 74% of patients without CNS involvement were grouped as high risk by CNS-IPI (*p* = 0.04) ([Table 2](#t2-kjim-2018-396){ref-type="table"}). CNS-directed therapy was combined with R-CHOP in 11 patients who had CNS involvement at diagnosis. Among these patients, five patients were alive without evidence of relapse. However, six patients died because of disease relapse or early mortality caused by infectious complications. In particular, one patient relapsed after CR, and all patients died from disease progression even after ASCT ([Fig. 3](#f3-kjim-2018-396){ref-type="fig"}). Likewise, the outcomes of four patients who had CNS relapse after R-CHOP chemotherapy were poor. Three of these patients died from disease progression, and only one patient was alive after being salvaged successfully by CNS-directed chemotherapy.

Survival analysis
-----------------

At a median follow-up of 47.0 months (95% confidence interval \[CI\], 25.0 to 69.0), the median OS was 45.0 months (95% CI, 25.8 to 64.2) ([Fig. 4A](#f4-kjim-2018-396){ref-type="fig"}). The median PFS was 23.0 months (95% CI, 4.5 to 41.5), and the OS was significantly worse in patients with relapse or disease progression ([Fig. 4B](#f4-kjim-2018-396){ref-type="fig"}). The presence of thrombocytopenia at diagnosis had a significant association with OS (*p* = 0.010) ([Fig. 4C](#f4-kjim-2018-396){ref-type="fig"}). As most patients (93%) had stage IV disease and belonged to the high or high-to-intermediate risk group according to the IPI and NCCN-IPI grades, these parameters could not discriminate patients with better and worse survival outcomes (data not shown). The CNS-IPI grading also failed to show a significant association with survival because 38 patients (83%) were grouped as having high risk CNS-IPI ([Table 1](#t1-kjim-2018-396){ref-type="table"}). Thus, the univariate analysis for OS using each parameter showed that only the presence of thrombocytopenia or anemia was significantly associated with a poor OS ([Table 3](#t3-kjim-2018-396){ref-type="table"}). The presence of HLH and CNS involvement at diagnosis were not significantly associated with poor survival outcomes ([Table 3](#t3-kjim-2018-396){ref-type="table"} and [Fig. 4D](#f4-kjim-2018-396){ref-type="fig"}). However, none of these parameters showed independent associations with overall survival in the multivariate analysis ([Table 3](#t3-kjim-2018-396){ref-type="table"}).

DISCUSSION
==========

In our study, clinical features were consistent with criteria for the diagnosis of the Asian variant of IVLBCL including cytopenia, hepatosplenomegaly, and histopathological features \[[@b15-kjim-2018-396]\]. The most common presenting symptoms were fever, neurologic symptoms, and dyspnea ([Fig. 1A](#f1-kjim-2018-396){ref-type="fig"}). All patients showed elevated levels of serum LDH, and more than 60% of them showed extremely elevated levels ([Fig. 1C](#f1-kjim-2018-396){ref-type="fig"}). Anemia and thrombocytopenia were also common and might be associated with HLH and hepatosplenomegaly ([Table 1](#t1-kjim-2018-396){ref-type="table"}). Therefore, if Asian patients with fever or neurologic symptoms show highly elevated levels of serum LDH and cytopenia, the possibility of IVLBCL should be considered.

Early studies in Japan evaluating patients with IVLBCL by immunohistochemistry showed that more than 75% of IVLBCL cases were the activated B-cell-like (ABC) type, and CD5, an unfavorable marker, was more frequently expressed in patients with IVLBCL than in those with DLBCL-NOS \[[@b1-kjim-2018-396],[@b3-kjim-2018-396]\]. A recent next-generation sequencing of 25 cases with IVLBCL also reported that 44% had *MYD88^L256P^* and 26% had *CD79b* mutations, known to be associated with poor prognosis \[[@b16-kjim-2018-396]\]. This double mutation was also identified by a recent study with exome sequencing of DLBCL biopsy samples, and its presence was significantly associated with poor prognosis, especially in the ABC type of DLBCL \[[@b17-kjim-2018-396]\]. Thus, the high prevalence of *MYD88^L256P^* and *CD79b* mutations might also be associated with tumor aggressiveness and the risk of treatment failure in patients with IVLBCL.

The addition of rituximab to chemotherapy was associated with an improved CR rate (90% vs. 50%, *p* = 0.04) and 3-year OS (89% vs. 38%, *p* = 0.01) compared with chemotherapy without it in Western patients \[[@b18-kjim-2018-396]\]. A Japanese study also demonstrated a better CR rate (82%) for patients given rituximab-containing chemotherapy rather than chemotherapy without rituximab (51%) \[[@b19-kjim-2018-396]\]. In our study, the median OS (45.0 months) ([Fig. 4A](#f4-kjim-2018-396){ref-type="fig"}) was similar to our previous case series reporting a median survival of 38.9 months in patients with an intravascular lymphoma treated with R-CHOP \[[@b20-kjim-2018-396]\]. However, our CR rate (67%, 31/46) was inferior to that of previous studies because eight patients showed disease progression immediately after the completion of R-CHOP even though they achieved CR at their interim response evaluation ([Fig. 2](#f2-kjim-2018-396){ref-type="fig"}). Furthermore, six patients died after the first or second cycle of R-CHOP (6/46, 13%), and the causes of death were treatment-related adverse event including cytopenia, infectious complications, and pulmonary hemorrhage. These complications might be associated with the severe toxic effects of rituximab. Actually, acute pulmonary failure after rituximab administration requiring rituximab interruption has been reported \[[@b19-kjim-2018-396]\]. Thus, delayed administration of rituximab in the first cycle of R-CHOP should be offered to patients with a high tumor burden to prevent the occurrence of severe infusion reaction in clinical practice.

We found here that 11/46 patients had CNS involvement at diagnosis (24%) by lumbar puncture of CSF or brain MRI. In addition, four patients developed CNS relapse during follow-up. Therefore, a total of 15 patients had CNS involvement with IVLBCL (33%, 15/46). However, the comparison of clinical features between patients with and without CNS involvement did not show significant differences ([Table 2](#t2-kjim-2018-396){ref-type="table"}). Furthermore, all patients with CNS involvement belonged to a high-risk group according to CNS-IPI, whereas 74% of patients without CNS involvement were also grouped as high-risk by CNS-IPI, although this was only marginally statistically significant (*p* = 0.04) ([Table 2](#t2-kjim-2018-396){ref-type="table"}). Thus, the risk stratification of CNS involvement as well as the prediction of CNS involvement based on the CNS-IPI score might not serve to identify patients at high risk of CNS involvement among patients with IVLBCL. Therefore, it might be difficult to establish a risk-adapted approach for the application of CNS prophylaxis in patients with the Asian variant of IVLBCL. Given the higher frequency of CNS involvement at diagnosis as well as CNS relapse in our study, a thorough evaluation of CNS including CSF analysis and brain MRI scans as well as active application of CNS prophylaxis should be considered as a routine practice for patients who are diagnosed with IVLBCL.

In our study, five patients survived out of 11 patients with CNS involvement at diagnosis after they were treated with R-CHOP plus CNS-directed therapy including high-dose MTX. As a result, the OS of patients with CNS involvement at diagnosis was not inferior to that of patients without CNS involvement at diagnosis ([Fig. 4D](#f4-kjim-2018-396){ref-type="fig"}). However, more effective treatment strategies should be developed to improve the outcome of patients with CNS involvement at diagnosis. On the other hand, the outcome of four patients who had CNS relapse after R-CHOP chemotherapy was extremely poor as three patients died from disease progression. This was consistent with the poor survival outcomes of patients with disease progression or relapse after R-CHOP ([Fig. 4B](#f4-kjim-2018-396){ref-type="fig"}). This result implies that the prognosis of patients might be extremely poor once disease has relapsed or progressed after the first-line treatment with R-CHOP regardless of salvage chemotherapy and ASCT. This suggests the need for more effective consolidation treatments for patients at high risk of treatment failure.

A registry-based study from the European Society for Blood and Marrow Transplantation (EBMT) suggested the favorable outcome of upfront ASCT in 11 patients with IVLBCL \[[@b21-kjim-2018-396]\]. Our study also showed better outcomes for upfront ASCT than for salvage ASCT because two patients receiving upfront ASCT including one patient with CNS involvement were still alive without relapse at the end of the study period ([Fig. 3](#f3-kjim-2018-396){ref-type="fig"}). However, the numbers were too small in our study and that of the EBMT. Given that more than 60% of patients with CR after R-CHOP maintained their response without upfront ASCT, it might be important to select patients who are candidates for upfront ASCT rather than applying ASCT to all patients with IVLBCL.

In our study, only thrombocytopenia was significantly associated with a poor OS ([Fig. 4C](#f4-kjim-2018-396){ref-type="fig"}). However, it failed to show an independent association with poor OS in the multivariate analysis ([Table 3](#t3-kjim-2018-396){ref-type="table"}). Other parameters that were believed to be unfavorable, such as the presence of HLH, did not show prognostic relevance. As this lack of significant risk factors for poor survival outcomes might be associated with the relatively few patients in our study as well as the retrospective nature of the study, a well-designed prospective study with a larger study population is warranted to explore prognostic factors for IVLBCL and the role of upfront ASCT in the future.

KEY MESSAGE
===========

1\. The median overall survival of patients with Asian variant of intravascular large B-cell lymphoma was 45.0 months, and overall survival was not different according to the involvement of central nervous system (CNS).

2\. The prediction of CNS involvement based on the clinical features including CNS-International Prognostic Index might not serve to identify patients at high risk of CNS involvement.
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![(A) Clinically presenting symptoms of the 46 patients. (B) The order of frequently involved organs. (C) Hemoglobin level (g/dL), platelet count (× 10^6^ /L), and serum lactate dehydrogenase (LDH) level (IU/L) at diagnosis.](kjim-2018-396f1){#f1-kjim-2018-396}

![Treatment outcomes for the 46 patients. R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; ASCT, autologous stem cell transplantation.](kjim-2018-396f2){#f2-kjim-2018-396}

![Clinical course and outcome of 11 patients with central nervous system (CNS) involvement at diagnosis. R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; IT, intrathecal chemotherapy; HD-MTX, high-dose methotrexate; IMVP16/PD, ifosfamide, methotrexate, etoposide and prednisone; ASCT, autologous stem cell transplantation; RMVP, rituximab, methotrexate, vincristine and procarbazine; ICE, ifosfamide, carboplatin and etoposide; \#, number of cycles.](kjim-2018-396f3){#f3-kjim-2018-396}

![(A) Overall survival curves of the 46 patients. (B) The overall survival is significantly worse in patients with relapse or disease progression. (C) The overall survival is significantly associated with the presence of thrombocytopenia. (D) The overall survival is not different between patients with and without central nervous system (CNS) involvement at diagnosis. CR, complete response.](kjim-2018-396f4){#f4-kjim-2018-396}

###### 

Characteristics of the patients (n = 46)

  Characteristic                       No. (%)
  ------------------------------------ -----------
  Sex                                  
   Male                                26 (57)
   Female                              20 (43)
  Age, yr                              
   ≤ 60                                20 (44)
   \> 60 to \< 75                      18 (39)
   ≥ 75                                8 (17)
  Eastern Cooperative Oncology Group   
   0/1                                 10 (22)
   ≥ 2                                 36 (78)
  Serum LDH                            
   Normal                              0
   Increased \> 1 to ≤ 3               16 (35)
   Increased \> 3                      30 (65)
  B symptoms                           
   Absence                             15 (33)
   Presence                            31 (67)
  Stage                                
   I/II                                1/2 (7)
   III/IV                              1/42 (93)
  Bone marrow involvement              
   Absence                             21 (46)
   Presence                            25 (54)
  No. of extranodal involvement        
   0/1                                 4/11 (33)
   ≥ 2                                 31 (67)
  Hepatomegaly and/or splenomegaly     
   Absence                             20 (43)
   Presence                            26 (57)
  Hemoglobin \< 11 g/dL                
   Absence                             18 (39)
   Presence                            28 (61)
  Platelet count \< 100 × 10^9^/L      
   Absence                             26 (57)
   Presence                            20 (43)
  Lymphadenopathy                      
   Absence                             24 (52)
   Presence                            22 (48)
  Serum albumin                        
   Normal                              19 (41)
   Decreased (\< 3.5 g/dL)             27 (59)
  IPI                                  
   L/LI                                2 (4)
   HI/H                                44 (96)
  NCCN-IPI                             
   L/LI                                2 (4)
   HI/H                                44 (96)
  CNS-IPI                              
   Low                                 0
   Intermediate                        8 (17)
   High                                38 (83)
  Hemophagocytic lymphohistiocytosis   
   Absence                             30 (65)
   Presence                            16 (35)

LDH, lactate dehydrogenase; IPI, International Prognostic Index; L/LI, low/low-intermediate; HI/H, high-intermediate/high; NCCN, National Comprehensive Cancer Network; CNS, central nervous system.

###### 

Comparison of patients with and without CNS involvement

  Characteristic                                                                                                                 CNS involvement   *p* value   
  ------------------------------------------------------------------------------------------------------------------------------ ----------------- ----------- -------
  Sex                                                                                                                                                          0.128
   Male                                                                                                                          11 (73)           15 (48)     
   Female                                                                                                                        4 (27)            16 (52)     
  Age, yr                                                                                                                                                      0.341
   ≤ 60                                                                                                                          8 (53)            11 (36)     
   \> 60                                                                                                                         7 (47)            20 (64)     
  ECOG                                                                                                                                                         0.999
   0/1                                                                                                                           3 (20)            7 (23)      
   ≥ 2                                                                                                                           12 (80)           24 (77)     
  Serum LDH                                                                                                                                                    0.520
   Increased ≤ 3                                                                                                                 4 (27)            12 (39)     
   Increased \> 3                                                                                                                11 (73)           19 (61)     
  B symptoms                                                                                                                                                   0.514
   Absence                                                                                                                       6 (40)            9 (29)      
   Presence                                                                                                                      9 (60)            22 (71)     
  Stage                                                                                                                                                        0.541
   I/II                                                                                                                          0                 3 (10)      
   III/IV                                                                                                                        15 (100)          28 (90)     
  Bone marrow involvement                                                                                                                                      0.999
   Absence                                                                                                                       7 (47)            14 (45)     
   Presence                                                                                                                      8 (53)            17 (55)     
  No. of extranodal involvement                                                                                                                                0.317
   0/1                                                                                                                           3 (20)            12 (39)     
   ≥ 2                                                                                                                           12 (80)           19 (61)     
  Hepatosplenomegaly                                                                                                                                           0.204
   Absence                                                                                                                       9 (60)            11 (36)     
   Presence                                                                                                                      6 (40)            20 (64)     
  Anemia^[a](#tfn1-kjim-2018-396){ref-type="table-fn"}^ and/or thrombocytopenia^[a](#tfn1-kjim-2018-396){ref-type="table-fn"}^                                 0.758
   Absence                                                                                                                       5 (33)            12 (39)     
   Presence                                                                                                                      10 (67)           19 (61)     
  Serum albumin, g/dL                                                                                                                                          0.752
   ≥ 3.5                                                                                                                         7 (47)            12 (39)     
   \< 3.5                                                                                                                        8 (53)            19 (61)     
  IPI                                                                                                                                                          0.551
   L/LI                                                                                                                          0                 2 (6)       
   HI/H                                                                                                                          15 (100)          29 (94)     
  NCCN-IPI                                                                                                                                                     0.551
   L/LI                                                                                                                          0                 2 (6)       
   HI/H                                                                                                                          15 (100)          29 (94)     
  CNS-IPI                                                                                                                                                      0.040
   Low                                                                                                                           0                 0           
   Intermediate                                                                                                                  0                 8 (26)      
   High                                                                                                                          15 (100)          23 (74)     
  Hemophagocytic lymphohistiocytosis                                                                                                                           0.520
   Absence                                                                                                                       11 (73)           19 (61)     
   Presence                                                                                                                      4 (26.7)          12 (39)     

Values are presented as number (%).

CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; IPI, International Prognostic Index; L/LI, low/low-intermediate; HI/H, high-intermediate/high; NCCN, National Comprehensive Cancer Network.

Hemoglobin \< 11 g/dL, platelet count \< 100 × 10^9^/L.

###### 

Univariate and multivariate analysis for overall survival

  Variable                                                         Univariate analysis   Multivariate analysis                                   
  ---------------------------------------------------------------- --------------------- ----------------------- ------- ------- --------------- -------
  Male sex                                                         0.733                 0.323--1.664            0.457   1.064   0.366--3.096    0.910
  Age \> 60 yr                                                     1.389                 0.600--3.217            0.443   1.156   0.440--3.034    0.768
  ECOG ≥ 2                                                         4.092                 0.957--17.500           0.057   5.902   0.899--38.741   0.064
  B symptoms                                                       1.436                 0.586--3.520            0.429   0.611   0.189--1.978    0.411
  Serum LDH elevation (\> 3)                                       1.322                 0.542--3.224            0.539   0.404   0.122--1.334    0.137
  Hemoglobin \< 11 g/dL                                            2.587                 1.014--6.597            0.047   2.182   0.578--8.235    0.250
  Platelet count \< 100 × 10^9^/L                                  2.865                 1.233--6.652            0.014   1.641   0.497--5.425    0.417
  Hepatosplenomegaly                                               2.313                 0.946--5.656            0.066   1.182   0.378--3.702    0.774
  Bone marrow involvement                                          1.849                 0.779--4.390            0.164   1.025   0.345--3.045    0.964
  High-risk of CNS-IPI                                             2.705                 0.629--11.628           0.181   1.783   0.286--11.115   0.536
  Presence of HLH                                                  1.157                 0.468--2.863            0.752   1.061   0.348--3.235    0.917
  CNS involvement^[a](#tfn2-kjim-2018-396){ref-type="table-fn"}^   0.723                 0.267--1.957            0.723   0.508   0.131--1.980    0.329

HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; CNS, central nervous system; IPI, International Prognostic Index; HLH, hemophagocytic lymphohistiocytosis.

CNS involvement at diagnosis (n = 11).
